A Novel Hybrid Sequence-Based Model for Identifying Anticancer Peptides
AbstractCancer is a serious health issue worldwide. Traditional treatment methods focus on killing cancer cells by using anticancer drugs or radiation therapy, but the cost of these methods is quite high, and in addition there are side effects. With the discovery of anticancer peptides, great progress has been made in cancer treatment. For the purpose of prompting the application of anticancer peptides in cancer treatment, it is necessary to use computational methods to identify anticancer peptides (ACPs). In this paper, we propose a sequence-based model for identifying ACPs (SAP). In our proposed SAP, the peptide is represented by 400D features or 400D features with g-gap dipeptide features, and then the unrelated features are pruned using the maximum relevance-maximum distance method. The experimental results demonstrate that our model performs better than some existing methods. Furthermore, our model has also been extended to other classifiers, and the performance is stable compared with some state-of-the-art works. View Full-Text
Share & Cite This Article
Xu, L.; Liang, G.; Wang, L.; Liao, C. A Novel Hybrid Sequence-Based Model for Identifying Anticancer Peptides. Genes 2018, 9, 158.
Xu L, Liang G, Wang L, Liao C. A Novel Hybrid Sequence-Based Model for Identifying Anticancer Peptides. Genes. 2018; 9(3):158.Chicago/Turabian Style
Xu, Lei; Liang, Guangmin; Wang, Longjie; Liao, Changrui. 2018. "A Novel Hybrid Sequence-Based Model for Identifying Anticancer Peptides." Genes 9, no. 3: 158.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.